Juventas Therapeutics
Juventas Therapeutics (acquired by Astellas) is developing novel regenerative medicine technologies from the Cleveland Clinic for treatment of cardiovascular disease. The company’s lead product, Stromal Derived Factor-1 (SDF-1) has been shown to significantly improve cardiac function through promoting cell survival and revascularization following a heart attack. The company is also pursuing opportunities in the areas of critical limb ischemia and wound repair.